• Original article (Clinical research) • Previous Articles     Next Articles

Effects of atorvastatin on hypertension patients with dyslipidemia and body's inflammatory response

HUANG Hai-yuan1, PAN Xing-shou1, HUANG Xian-nan1, ZHOU Liu-fang1, LIU Yan1, LUO Wei1, FU Huang-de2   

  1. 1.Department of Cardiovascular Medicine, 2.Department of Neurosurgery，the Affiliated Hospital of Youjiang Medical University for Nationalities， Baise 533000, China
  • Online:2014-11-28 Published:2014-12-02

PDF (PC)

1119

Abstract:

Objective To investigate the effects of atorvastatin on hypertension patients with dyslipidemia and body's inflammatory response. Methods A total of 120 hypertension patients with dyslipidemia were selected and randomly divided into the combined drug group (n=60) and single drug group (n=60) and 60 healthy volunteers were selected as the control group. Patients of the single drug group administrated levamlodipine besylate tablets (2.5 mg/d) and patients of the combined drug group administrated same dose of levamlodipine besylate tablets and atorvastatin (20 mg/d) for 8 weeks. The effects of two therapeutic regimens on the anti-hypertension, blood lipid level, carotid-femoral pulse wave velocity (cfPWV), serum high-sensitivity C-reactive protein (hs-CRP) level, serum matrix metalloproteinase-9 (MMP-9) level, and serum inflammatory cytokine level were compared. Results Symptoms of hypertension of two groups were controlled and improved at different degrees after treatment. Fifty-eight cases of the combined drug group were markedly effective or effective and the overall response rate was 96.67%, while 44 cases of the single drug group were markedly effective or effective and the overall response rate was 73.33%, which was significantly lower than that of the combined drug group (P<0.05). The TC, TG, LDL-C, IL-4, IL-6, MMP-9, and hs-CRP levels and cfPWV of two groups significantly decreased after treatment, while HDL-C and IL-10 levels significantly increased in both groups (P<0.05). Variations of above indexes of the combined drug group were significantly superior than those of the single drug group (P<0.05). The blood pressure values significantly and positively correlated to IL-4, IL-6, MMP-9, hs-CRP, and cfPWV, while significantly and negatively correlated to IL-10. Conclusion Atorvastatin has significant clinical effects on hypertension patients with dyslipidemia and can efficiently inhibit the body's inflammatory response.

Key words: atorvastatin, hypertension, high-sensitivity C-reactive protein, matrix metalloproteinase-9, inflammatory cytokine